Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    82.57
    -0.24 (-0.29%)
     
  • GOLD FUTURES

    2,341.50
    +3.10 (+0.13%)
     
  • DOW

    38,021.30
    -439.62 (-1.14%)
     
  • Bitcoin GBP

    51,580.44
    -195.57 (-0.38%)
     
  • CMC Crypto 200

    1,390.58
    +8.01 (+0.58%)
     
  • NASDAQ Composite

    15,556.96
    -155.79 (-0.99%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Investors Who Bought CymaBay Therapeutics (NASDAQ:CBAY) Shares Three Years Ago Are Now Up 168%

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) shareholders might be concerned after seeing the share price drop 28% in the last quarter. But in three years the returns have been great. Indeed, the share price is up a very strong 168% in that time. To some, the recent share price pullback wouldn't be surprising after such a good run. The fundamental business performance will ultimately dictate whether the top is in, or if this is a stellar buying opportunity.

Check out our latest analysis for CymaBay Therapeutics

CymaBay Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

ADVERTISEMENT

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

NasdaqGS:CBAY Income Statement, September 28th 2019
NasdaqGS:CBAY Income Statement, September 28th 2019

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Investors in CymaBay Therapeutics had a tough year, with a total loss of 53%, against a market gain of about 1.9%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9.7% over the last half decade. We realise that Buffett has said investors should 'buy when there is blood on the streets', but we caution that investors should first be sure they are buying a high quality businesses. It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.